Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

USA - NASDAQ:EXEL - US30161Q1040 - Common Stock

41.65 USD
-0.7 (-1.65%)
Last: 11/14/2025, 8:00:01 PM
42.36 USD
+0.71 (+1.7%)
After Hours: 11/14/2025, 8:00:01 PM
Fundamental Rating

8

Overall EXEL gets a fundamental rating of 8 out of 10. We evaluated EXEL against 533 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. With these ratings, EXEL could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
In the past 5 years EXEL has always been profitable.
Each year in the past 5 years EXEL had a positive operating cash flow.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of 24.01%, EXEL belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.
EXEL has a better Return On Equity (31.37%) than 97.37% of its industry peers.
EXEL has a better Return On Invested Capital (26.31%) than 98.50% of its industry peers.
EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is significantly below the industry average of 15.78%.
The last Return On Invested Capital (26.31%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROIC 26.31%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

Looking at the Profit Margin, with a value of 29.63%, EXEL belongs to the top of the industry, outperforming 95.87% of the companies in the same industry.
In the last couple of years the Profit Margin of EXEL has declined.
Looking at the Operating Margin, with a value of 35.85%, EXEL belongs to the top of the industry, outperforming 97.75% of the companies in the same industry.
EXEL's Operating Margin has declined in the last couple of years.
EXEL's Gross Margin of 96.63% is amongst the best of the industry. EXEL outperforms 95.87% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has less shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

EXEL has an Altman-Z score of 12.30. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL has a better Altman-Z score (12.30) than 86.12% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.3
ROIC/WACC3
WACC8.78%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

EXEL has a Current Ratio of 3.75. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Current ratio (3.75) which is in line with its industry peers.
EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EXEL (3.68) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.68
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.93%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%

3.2 Future

Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.04% on average per year.
The Revenue is expected to grow by 10.30% on average over the next years. This is quite good.
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y22.04%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y10.3%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 17.57, the valuation of EXEL can be described as rather expensive.
EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 94.93% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. EXEL is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 14.35 indicates a correct valuation of EXEL.
96.06% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, EXEL is valued rather cheaply.
Industry RankSector Rank
PE 17.57
Fwd PE 14.35
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 96.06% of the companies are valued more expensively.
96.62% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 14.38
EV/EBITDA 11.31
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 26.07% in the coming years.
PEG (NY)0.59
PEG (5Y)1.39
EPS Next 2Y25.25%
EPS Next 3Y26.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (11/14/2025, 8:00:01 PM)

After market: 42.36 +0.71 (+1.7%)

41.65

-0.7 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)N/A N/A
Inst Owners96.89%
Inst Owner Change-0.16%
Ins Owners2.23%
Ins Owner Change-2.45%
Market Cap11.21B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts78.46
Price Target44.77 (7.49%)
Short Float %7.94%
Short Ratio7.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)-0.95%
PT rev (3m)-3.25%
EPS NQ rev (1m)9.1%
EPS NQ rev (3m)9.7%
EPS NY rev (1m)-0.86%
EPS NY rev (3m)2.04%
Revenue NQ rev (1m)0.52%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE 17.57
Fwd PE 14.35
P/S 4.9
P/FCF 14.38
P/OCF 14.17
P/B 5.19
P/tB 5.35
EV/EBITDA 11.31
EPS(TTM)2.37
EY5.69%
EPS(NY)2.9
Fwd EY6.97%
FCF(TTM)2.9
FCFY6.95%
OCF(TTM)2.94
OCFY7.05%
SpS8.5
BVpS8.03
TBVpS7.79
PEG (NY)0.59
PEG (5Y)1.39
Graham Number20.69
Profitability
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROCE 33.48%
ROIC 26.31%
ROICexc 44.11%
ROICexgc 46.12%
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
FCFM 34.08%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 37.81%
Cap/Sales 0.49%
Interest Coverage 250
Cash Conversion 93.06%
Profit Quality 115.03%
Current Ratio 3.75
Quick Ratio 3.68
Altman-Z 12.3
F-Score8
WACC8.78%
ROIC/WACC3
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y29.57%
EPS Next 2Y25.25%
EPS Next 3Y26.07%
EPS Next 5Y22.04%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.2%
Revenue Next 2Y9.82%
Revenue Next 3Y11.52%
Revenue Next 5Y10.3%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%

EXELIXIS INC / EXEL FAQ

What is the fundamental rating for EXEL stock?

ChartMill assigns a fundamental rating of 8 / 10 to EXEL.


What is the valuation status for EXEL stock?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.


What is the profitability of EXEL stock?

EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.


What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?

The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 17.57 and the Price/Book (PB) ratio is 5.19.